Business Wire

Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
Nasdaq

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...
Nasdaq

Voyager Therapeutics Publishes Data on ALPL's Role in AAV Transport Across the Blood-Brain Barrier

Voyager Therapeutics, Inc. announced the peer-reviewed publication of groundbreaking research showcasing the role of alkaline phosphatase (ALPL) in transporting a novel AAV capsid, VCAP-102, across ...
Morningstar

Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments

Apertura has licensed its novel TfR1 capsid (TfR1 CapX) to partners targeting CNS disorders TfR1 CapX enables broad brain distribution via intravenous dosing, meeting the urgent need for a ...